Driehaus Capital Management’s Krystal Biotech KRYS Stock Holding History

Driehaus Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-121,702	Closed	-$19.1M	–	437
2024 Q4	$19.1M	Sell	121,702 -41,602	-25%	-$7.38M	0.16%	178
2024 Q3	$29.7M	Buy	163,304 +44,558	+38%	+$8.59M	0.26%	124
2024 Q2	$21.8M	Buy	118,746 +8,547	+8%	+$1.43M	0.21%	138
2024 Q1	$19.6M	Sell	110,199 -86,187	-44%	-$12M	0.2%	151
2023 Q4	$24.4M	Sell	196,386 -2,297	-1%	-$255K	0.29%	106
2023 Q3	$23M	Buy	198,683 +90	+0%	+$11K	0.3%	108
2023 Q2	$23.3M	Buy	198,593 +144,661	+268%	+$14.8M	0.29%	110
2023 Q1	$4.32M	Buy	+53,932	New	+$4.24M	0.06%	303

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Driehaus Capital Management's KRYS Position: Q1 2025 in Review

Driehaus Capital Management sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 121,702 shares — an estimated $19.1M sold.

Driehaus Capital Management first reported a position in KRYS in Q1 2023 and held it in 8 quarters. The position peaked at $29.7M in Q3 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

Driehaus Capital Management reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
Driehaus Capital Management sold 121,702 Krystal Biotech shares in Q1 2025, an estimated $19.1M.
Driehaus Capital Management first reported a position in Krystal Biotech in Q1 2023 and held it in 8 quarters.
Driehaus Capital Management's Krystal Biotech position peaked at $29.7M in Q3 2024.
299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Driehaus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.